Cargando…
Long‐term cardiovascular effects of vandetanib and pazopanib in normotensive rats
Vandetanib and pazopanib are clinically available, multi‐targeted inhibitors of vascular endothelial growth factor (VEGF) and platelet‐derived growth factor (PDGF) receptor tyrosine kinases. Short‐term VEGF receptor inhibition is associated with hypertension in 15%‐60% of patients, which may limit t...
Autores principales: | Cooper, Samantha L., Carter, Joanne J., March, Julie, Woolard, Jeanette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543457/ https://www.ncbi.nlm.nih.gov/pubmed/31164986 http://dx.doi.org/10.1002/prp2.477 |
Ejemplares similares
-
Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib
por: Jáklová, Kateřina, et al.
Publicado: (2021) -
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension
por: Milling, Rikke Vilsbøll, et al.
Publicado: (2018) -
Vandetanib
por: Vozniak, J. Michael, et al.
Publicado: (2012) -
Radiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib
por: Znati, Sami, et al.
Publicado: (2020) -
The effect of two selective A(1)‐receptor agonists and the bitopic ligand VCP746 on heart rate and regional vascular conductance in conscious rats
por: Cooper, Samantha L., et al.
Publicado: (2020)